Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
May 19 2022 - 1:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today was officially
recognized as the number one philanthropic funder of HIV-related
programs in a new tracking report released by Funders Concerned
About AIDS (FCAA). The report, found at:
https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/,
is released annually and is widely regarded as the most
comprehensive study of its kind. It analyzes 2020 funding data (the
most recent year available) revealing that Gilead’s philanthropic
support wholly drove the increase of private HIV and AIDS
philanthropic funding – representing 38% of all HIV funding and
driving a majority of the increases in funding across all issues,
populations and geographies. Gilead is also recognized in the
report as the number one funder in the U.S. and the number three
funder internationally. The report indicates that, “Private HIV and
AIDS philanthropic funding to the U.S. rose for the seventh year in
a row, totaling over $321 million in 2020, a dramatic 52% ($109
million) increase from 2019.”
In addition to being recognized as the number one funder both
overall and in the U.S., Gilead was also recognized as the number
one funder across a range of categories, including:
- Number one funder addressing the COVID-19 pandemic
- Number one funder of Black, Indigenous and people of color
communities in the U.S.
- Number one corporate funder
“Gilead's support for community organizations is part of our
enduring commitment to ending the HIV epidemic,” said Daniel O’Day,
Chairman and Chief Executive Officer, Gilead Sciences. “We believe
that real progress is only possible through collaboration and
partnership. That is why we invest in the extraordinary efforts our
partners are undertaking to reach underserved populations,
eliminate barriers to care and educate communities. It is inspiring
to see the work that goes on across these groups and we are proud
to play a role in supporting them.”
Gilead’s philanthropic efforts are administered through a number
of signature initiatives and programs designed to reach key
populations and communities across the U.S. and around the
world.
RADIAN®, launched in 2019 with the Elton John AIDS Foundation,
addresses challenges in Eastern Europe and Central Asia, where the
annual rate of HIV diagnoses continues to rise. In the U.S., HIV
Age Positively® aims to improve the health and quality of life for
those who are aging and TRANScend® supports Trans-led organizations
improving the safety, health and wellness of the Transgender
community.
To assist grantees who faced imminent closure or termination of
services as a result of the COVID-19 pandemic, Gilead CARES was
launched in 2020, providing up to $20 million in donations to
nonprofit groups. The Gilead COMPASS Initiative®, a 10-year, $100+
million partnership with community-based organizations, is working
to combat the HIV epidemic in the Southern United States, and is
responsible for driving sharp increases in funding across the U.S.
South, which had been in decline over the previous two years.
According to the report, “In 2020, funding disbursements to the
U.S. South increased sharply, by $28 million (76%), after having
declined the two previous years. Again, as in 2017, this increase
is largely attributed to large disbursements for Gilead’s COMPASS
Initiative. COMPASS funding is distributed to its coordinating
centers, located across the U.S. South, in large sums, but is then
granted out into the community over a couple of years.”
More information about Gilead’s signature funding initiatives
and programs can be found at:
https://www.gilead.com/purpose/partnerships-and-community
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis and cancer. Gilead operates in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more than 30 years, Gilead has been a leading innovator in
the field of HIV, driving advances in treatment, prevention and
cure research. Today, millions of people living with HIV globally
receive antiretroviral therapy provided by Gilead or one of the
company’s manufacturing partners.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517006264/en/
Jacquie Ross, Investors (408) 656-8793
Hayley Home, Media (916) 402-2864
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024